Concepedia

Publication | Open Access

Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC

DOIFull Paper Access

48

Citations

0

References

2016

Year

Marcin Kowanetz, Wei Zou, David S. Shames, C. Cummings, Naiyer A. Rizvi, Alexander I. Spira, Garrett M. Frampton, Vincent Lévêque, Shannon L. Flynn, Simonetta Mocci,
Annals of Oncology

No additional data available for this publication yet. Check back later!